Study on Safety and Effectiveness of Three Doses of Argatroban as Anticoagulant in Percutaneous Coronary Intervention (PCI)
Status:
Completed
Trial end date:
2006-10-01
Target enrollment:
Participant gender:
Summary
This is a phase II multi-centre study in 140 patients undergoing elective PCI to obtain the
information on dose-response of argatroban in pharmacodynamic markers and to assess the
anticoagulation, safety and efficacy of argatroban in reference to unfractionated heparin, in
combination with dual antiplatelet therapy.